Practice Areas
Life Sciences, PatentsIndustry & Technical Focus
Biotechnology, Chemistry, Pharmaceuticals, Genomics, Biochemistry, Molecular and Cell Biology, Immunotherapeutics, RNAi
Practice Description
Dr. Milasincic practices in all areas of biotechnology patent law including patent prosecution, opinion work, and licensing. She has over 10 years of experience assisting pharmaceutical, biotech, health care, and university clients with domestic and foreign patent prosecution.
Debra completed her post-doctoral fellowship in biochemistry at Boston University School of Medicine and has published her research in several scientific journals.
Notable Experience
- Managing the patent portfolios for a major university medical school in the field of RNAi.
- Conducting an extensive IP due diligence review for a Japanese pharmaceutical company which resulted in its $325 million acquisition of an antibody company.
- Managing the patent portfolios for a leading pharmaceutical company collaboration in the field of Alzheimer’s disease immunotherapeutics, including obtaining patent protection for several lead clinical candidate therapeutics.
Publications & Speaking Engagements
- Speaker, “Project Management and IP,” Massachusetts Biotechnology Council, January 20, 2009.
- Co-author, “Critical proliferation-independent window for basic fibroblast growth factor repression of myogenesis via the p42/p44 MAPK signaling pathway,” J Biol Chem,276(17):13709-17. (2001)
- Co-author, “Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and –independent pathways,” Mol Cell Biol,16(11):5964-73. (1996)
- Co-author, “Anchorage-dependent control of muscle-specific gene expression in C2C12 mouse myoblasts,” In Vitro Cell Dev Biol Anim, 32(2):90-9. (1996)
- Co-author, “Dynamic equilibria between subcomponents of C1, the first component of human complement,” Mol Immunol., 29(1):45-51. (1992)
